Accelerated hematopoietic recovery and protective effect of the cyclooxygenase inhibitor indomethacin in bacterial infection of neutropenic mice
- PMID: 8453676
- DOI: 10.1006/cimm.1993.1074
Accelerated hematopoietic recovery and protective effect of the cyclooxygenase inhibitor indomethacin in bacterial infection of neutropenic mice
Abstract
The effects of indomethacin administration on Pseudomonas aeruginosa infection were investigated in neutropenic mice. Cyclophosphamide-treated mice received the drug at 2.5 to 12 mg/kg according to different regimens, to be challenged with a lethal intraperitoneal inoculum of P. aeruginosa 5 days after myelosuppression. A single exposure of the neutropenic mice to 7 mg/kg indomethacin during the first 6 to 48 hr after myelosuppression was found to optimally restore the animals' antibacterial resistance, both in terms of survival of infected mice and clearance of the organisms from the peritoneal cavity. However, when administered 24 hr before challenge, the same drug dosage had no effect in enhancing survival. Cure was associated with accelerated hematopoietic recovery, as revealed by peripheral blood leukocyte counts, spleen weight and cellularity, cellular response to infection in the peritoneal cavity, and enumeration in vitro of bone marrow and splenic granulocyte-macrophage colony-forming cells. Following indomethacin administration, a rapid burst in the levels of colony-stimulating activity was detected in the bloodstream, and exposure of splenic macrophages or marrow cells to indomethacin in vitro was found to result in enhanced expression of transcripts specific for granulocyte-macrophage colony-stimulating factor. These data support the notion that the administration of cyclooxygenase inhibitors may be useful in promoting hematopoiesis and reducing the risk of opportunistic infections in myelosuppressed hosts.
Similar articles
-
Antibacterial resistance induced by recombinant interleukin 1 in myelosuppressed mice: effect of treatment schedule and correlation with colony-stimulating activity in the bloodstream.Cell Immunol. 1990 Jun;128(1):250-60. doi: 10.1016/0008-8749(90)90023-k. Cell Immunol. 1990. PMID: 2111738
-
Protection against gram-negative bacteremia in neutropenic mice with recombinant granulocyte-macrophage colony-stimulating factor.Cytokine. 1990 Jul;2(4):287-93. doi: 10.1016/1043-4666(90)90030-w. Cytokine. 1990. PMID: 1966550
-
Indomethacin augments granulocyte-macrophage colony-stimulating factor-induced hematopoiesis following 5-FU treatment.Exp Hematol. 1990 Oct;18(9):974-8. Exp Hematol. 1990. PMID: 2204540
-
In vitro and in vivo hematopoietic activities of Betafectin PGG-glucan.Exp Hematol. 1998 Dec;26(13):1247-54. Exp Hematol. 1998. PMID: 9845381
-
[Prevention and treatment of febrile neutropenia].Tumori. 1997;83(2 Suppl):S15-9. Tumori. 1997. PMID: 9235724 Review. Italian.
Cited by
-
Allergenic sensitization prevents upregulation of haemopoiesis by cyclo-oxygenase inhibitors in mice.Br J Pharmacol. 2002 Mar;135(5):1315-23. doi: 10.1038/sj.bjp.0704580. Br J Pharmacol. 2002. PMID: 11877341 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources